Beam Therapeutics (BEAM) Interest Expenses (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Interest Expenses data on file, last reported at $960000.0 in Q1 2026.

• On a quarterly basis, Interest Expenses rose 734.78% year-over-year to $960000.0 in Q1 2026; TTM through Mar 2026 was $48.4 million, a 41962.61% increase from a year earlier, with the FY2025 full-year figure at $53.8 million, down 87.71% from the prior year.
• Interest Expenses for Q1 2026 stood at $960000.0, up from $13000.0 in the prior quarter.
• Over the last five years, Interest Expenses for BEAM reached as high as $96.3 million in Q2 2022 and fell as low as $2000.0 in Q3 2024.
• Historically, Interest Expenses has averaged $10.8 million across 5 years, with a median of $456500.0 in 2023.
• Across the five-year window, Interest Expenses soared 29456.58% in 2023 and sank 99.59% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $76000.0 in 2022, then surged by 29456.58% to $22.5 million in 2023, then increased by 11.07% to $24.9 million in 2024, then slumped by 99.95% to $13000.0 in 2025, then jumped by 7284.62% to $960000.0 in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $960000.0 in Q1 2026, $13000.0 in Q3 2025, and $52000.0 in Q2 2025.